Nivolumab (Opdivo) demonstrated durable response and overall survival (OS) rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).1
These findings support the CheckMate-141 safety and activity data in this population, which historically has had a poor prognosis.
“These promising results encourage the use of nivolumab in this population, but further follow-up and more mature data are still needed,” concluded Bruixola and colleagues.
- Bruixola G, Caballero Daroqui J, Cunquero Tomas AJ, et al. Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastatic head and neck squamous cell (PR R/M HNSCC) patients (pts): real-life experience. Ann Oncol. 2018;29(Suppl 8):viii372-viii399. doi: 10.1158/1538-7445.AM2018-CT116.
- Ferris RL, Blumenschein GR, Fayette J, et al. Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. In: Proceedings from the American Association for Cancer Research Annual Meeting 2018; April 14-18, 2018; Chicago, Illinois. Abstract CT116. doi: 10.1158/1538-7445.AM2018-CT116.
... to read the full story